What's Happening?
BridgeBio and Alnylam are entering the ATTR-cardiomyopathy market, challenging Pfizer's established presence with its transthyretin stabilizer tafamidis. BridgeBio's Attruby, approved in November 2024, targets and stabilizes transthyretin, a protein mutated in ATTR-cardiomyopathy. Alnylam's Amvuttra, an RNAi silencer, joined the market in March 2025. Despite Pfizer's strong sales of $5.4 billion for its tafamidis line in 2024, BridgeBio has reported promising uptake for Attruby, with over 1,000 unique prescriptions and significant revenue growth. Alnylam's Amvuttra is also performing well, indicating robust competition in the market.
AD
Why It's Important?
The entry of BridgeBio and Alnylam into the ATTR-cardiomyopathy market signifies increased competition and innovation in treatments for this condition. Pfizer's dominance is being challenged, potentially leading to more options and improved therapies for patients. This competition could drive advancements in drug development and pricing strategies, benefiting healthcare providers and patients alike. The success of these new entrants highlights the evolving landscape of biopharma, where smaller companies can compete with established giants, fostering a dynamic and competitive market environment.
What's Next?
As BridgeBio and Alnylam continue to establish their presence in the ATTR-CM market, further developments in drug efficacy and market share are anticipated. The companies may seek strategic partnerships or additional funding to bolster their commercial activities and expand their reach. Pfizer may respond with enhanced marketing strategies or new product developments to maintain its market position. The ongoing competition could lead to further innovations in ATTR-CM treatments, improving patient outcomes and expanding therapeutic options.
